Archives
-
Lopinavir: From HIV Potency to Repurposing Logic
2026-08-31
Lopinavir (ABT-378) combines picomolar HIV protease inhibition with activity against selected resistant variants. This article explains how its biochemical, cellular, serum, and repurposing data should guide assay design without confusing HIV potency with coronavirus efficacy.
-
MPC, Lactate, and Histone Lactylation in Tumor Immunity
2026-08-31
The reference study identifies a metabolic–epigenetic pathway in which reduced MPC1/MPC2 expression increases lactate, elevates histone lactylation in dendritic cells, and weakens CD8+ T-cell activity in colorectal cancer. Its findings connect mitochondrial pyruvate transport with tumor progression and anti-PD-1 response, offering a framework for studying how lactate metabolism shapes immunotherapy resistance.
-
DOPE: A Helper Lipid for Delivery and Ferroptosis
2026-08-30
1,2-Dioleoyl-sn-glycero-3-PE (DOPE) is a phosphatidylethanolamine helper lipid that supports acidic endosomal membrane fusion and nucleic acid release. A 2026 study also reported that exogenous DOPE partially restored developmental conidial-death defects in Magnaporthe oryzae mutants, but this fungal result does not by itself establish a delivery formulation or clinical application.
-
Tunicamycin for ER Stress and UPR Assays
2026-08-29
Tunicamycin is a mechanistically defined N-glycosylation inhibitor for building controlled ER-stress, macrophage inflammation, and proteostasis assays. This practical guide connects RAW264.7 workflows with new C. elegans evidence showing why calibrated, mild UPR activation can be more informative than maximal stress.
-
Tofacitinib Citrate: A Smarter Assay Framework
2026-08-28
Tofacitinib citrate is more than a JAK3 inhibitor: it is a context-dependent perturbation tool for immune regulation research. This guide integrates biochemical selectivity, lymphocyte assays, and endothelial inflammation data into a practical experimental framework.
-
Phenothiazines, ROS, and Macrophage Autophagy
2026-08-28
The reference study shows that phenothiazines strengthen macrophage control of intracellular bacteria through coordinated increases in lysosomal activity, reactive oxygen species, and autophagy. Its inhibitor and scavenger experiments support a host-directed antibacterial mechanism, while in vivo perphenazine data provide an initial translational bridge for infection and inflammation research.
-
AU-24118 and ABCB1-Mediated PROTAC Resistance
2026-08-28
The reference study introduces AU-24118, an orally bioavailable PROTAC degrader designed to eliminate mSWI/SNF ATPase components in castration-resistant prostate cancer. It also identifies SMARCA4 bromodomain mutations and ABCB1 overexpression as distinct acquired resistance mechanisms, showing that transporter-directed intervention can restore sensitivity to several PROTAC classes.
-
α2-AR Agonists in Osteosarcoma Recurrence
2026-08-27
The reference study evaluates local delivery of the α2-adrenergic receptor agonist UK14,304 in a thermo-sensitive hydrogel after osteosarcoma resection. Its findings support an immune-mediated reduction in recurrence, linked to CD8+ T-cell activity, T-cell receptor signaling, and ITGAL-centered regulation rather than direct tumor-cell toxicity.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-08-26
Yang et al. identify injured type II alveolar epithelial cells as a major source of accumulated lysophosphatidylcholine during bleomycin-induced pulmonary fibrosis and show that released LysoPC can activate lung fibroblasts. Their experiments connect reduced epithelial HMGCS2 to impaired lipid degradation through a PPARα–CPT1A/CPT2 axis, suggesting a mechanistically defined target for further fibrosis research.
-
Ceramides Drive RGNNV Infection: Lipidomics Insights
2026-08-26
Zhang and colleagues combine global lipidomics with pathway perturbation, protein localization, gene knockdown, and metabolic rescue to show that ceramide accumulation supports red-spotted grouper nervous necrosis virus replication. The study identifies ceramide flux and autophagy as mechanistically connected, while also defining important limits for translating cell-based findings into aquaculture interventions.
-
WM-8014: Time-Resolved Epigenetic Assay Design
2026-08-26
WM-8014 is a reversible KAT6A inhibitor for dissecting chromatin-dependent growth arrest without equating reduced proliferation with cell death. This guide connects its mechanism and model evidence with RESTRICT-seq principles to improve time-resolved cancer biology research and assay interpretation.
-
How Kinase Inhibitors Accelerate p38α Dephosphorylation
2026-08-25
The reference preprint shows that selected kinase inhibitors can both inhibit p38α catalysis and accelerate WIP1-mediated removal of its activation-loop phosphothreonine. This dual-action mechanism links inhibitor binding to kinase conformational control and suggests a route toward more durable and selective inhibition of p38 MAPK signaling.
-
Ruxolitinib: From JAK Biology to Immune Translation
2026-08-24
Ruxolitinib (INCB018424) is more than a selective JAK1/2 kinase inhibitor: it is a mechanistic tool for connecting JAK-STAT signaling pathway inhibition with progenitor-cell biology and tumor immune remodeling. This article outlines experimental strategies for myelofibrosis research, oncogenic JAK2 fusion protein studies, and combination immunotherapy models while distinguishing biochemical potency from translational evidence.
-
Bufalin: A Mechanistic Roadmap for TNBC Research
2026-08-24
Bufalin is more than a cardiotonic steroid with broad anticancer activity: emerging evidence positions it as a mechanism-led research probe that can connect direct target engagement, protein degradation, apoptosis, and translational modeling in triple-negative breast cancer. This article examines how STK33 biology, assay design, formulation discipline, and model selection can turn a natural-product signal into a more rigorous development hypothesis.
-
Honokiol Workflows for Cancer Drug Response
2026-08-23
Honokiol can help researchers separate growth inhibition, cell killing, NF-κB signaling, and oxidative-stress effects in cancer and inflammation models. This practical workflow combines dose preparation, time-resolved viability measurements, death confirmation, and mechanism-focused controls to reduce misleading single-assay conclusions.